Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636162 · ClinicalTrials.gov registry record · Early Phase 1
Window of Opportunity Study of DSP-0390 in Gliomas
A Early Phase 1 study of Glioma, Malignant and IDH Mutation, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06636162 is a Early Phase 1 study of Glioma, Malignant and IDH Mutation that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06636162, a Early Phase 1 study of Glioma, Malignant and IDH Mutation, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. The hypothesis is that DSP-0390 will accumulate in brain tumor tissue at pharmacologically relevant concentrations, and that alterations in cholesterol metabolism driven by mutant IDH will increase susceptibility to DSP-0390 and lead to tumor cell death.
Conditions Studied
Interventions
- DRUG DSP-0390
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-03 |
| Est. Completion | 2026-05-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06636162
The ClinicalTrials.gov registry entry for NCT06636162 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (68% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioma, Malignant appearing as the primary indexed condition, and to 1 intervention - of which DSP-0390 is the first listed.
NCT06636162 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06636162 about?
NCT06636162 is a clinical study titled "Window of Opportunity Study of DSP-0390 in Gliomas". This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points througho...
What is the current status of trial NCT06636162?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-03. Estimated completion is 2026-05-17.
What conditions does trial NCT06636162 study?
This clinical trial studies the following conditions: Glioma, Malignant, IDH Mutation, Grade II Glioma.
What interventions are being tested in trial NCT06636162?
The interventions under investigation include: DSP-0390 (DRUG).
Who is sponsoring clinical trial NCT06636162?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636162 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma, Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
RECRUITING · Early Phase 1
-
18F-Fluciclovine PET-MRI in High-grade Glioma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
Niraparib In Recurrent IDH 1/2 Gliomas
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.